KR20240109250A - 항ox40 단일클론 항체를 포함하는 약학적 제제 - Google Patents

항ox40 단일클론 항체를 포함하는 약학적 제제 Download PDF

Info

Publication number
KR20240109250A
KR20240109250A KR1020247016091A KR20247016091A KR20240109250A KR 20240109250 A KR20240109250 A KR 20240109250A KR 1020247016091 A KR1020247016091 A KR 1020247016091A KR 20247016091 A KR20247016091 A KR 20247016091A KR 20240109250 A KR20240109250 A KR 20240109250A
Authority
KR
South Korea
Prior art keywords
mmol
concentration
pharmaceutical
buffer
pharmaceutical formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247016091A
Other languages
English (en)
Korean (ko)
Inventor
치앙 순
시옹화 진
펭청 판
지하오 수
Original Assignee
인매진 피티이. 엘티디.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 인매진 피티이. 엘티디. filed Critical 인매진 피티이. 엘티디.
Publication of KR20240109250A publication Critical patent/KR20240109250A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020247016091A 2021-10-15 2022-10-13 항ox40 단일클론 항체를 포함하는 약학적 제제 Pending KR20240109250A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2021124200 2021-10-15
CNPCT/CN2021/124200 2021-10-15
CNPCT/CN2022/118065 2022-09-09
CN2022118065 2022-09-09
PCT/CN2022/125017 WO2023061424A1 (en) 2021-10-15 2022-10-13 Pharmaceutical formulation comprising anti-ox40 monoclonal antibody

Publications (1)

Publication Number Publication Date
KR20240109250A true KR20240109250A (ko) 2024-07-10

Family

ID=85987310

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247016091A Pending KR20240109250A (ko) 2021-10-15 2022-10-13 항ox40 단일클론 항체를 포함하는 약학적 제제

Country Status (13)

Country Link
US (1) US20250282882A1 (https=)
EP (1) EP4415754A4 (https=)
JP (1) JP2024538140A (https=)
KR (1) KR20240109250A (https=)
CN (1) CN118541166A (https=)
AU (1) AU2022367611A1 (https=)
CA (1) CA3235879A1 (https=)
CL (1) CL2024001157A1 (https=)
IL (1) IL312138A (https=)
MX (1) MX2024004619A (https=)
PE (1) PE20241351A1 (https=)
TW (1) TW202323280A (https=)
WO (1) WO2023061424A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20230255A1 (es) * 2020-04-17 2023-02-07 Hutchison Medipharma Ltd Anticuerpo anti-ox40 y usos del mismo
TW202600166A (zh) * 2024-03-04 2026-01-01 新加坡商創響私人有限公司 包含ｏｘ４０靶向抗體的藥物組合物及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100014588A (ko) * 2007-02-27 2010-02-10 제넨테크, 인크. 길항제 ｏｘ40 항체 및 염증성 및 자가면역 질환의 치료에서의 이의 용도
SG11201607969XA (en) * 2014-03-31 2016-10-28 Genentech Inc Anti-ox40 antibodies and methods of use
WO2017134292A1 (en) * 2016-02-04 2017-08-10 Glenmark Pharmaceuticals S.A. Anti-ox40 antagonistic antibodies for the treatment of atopic dermatitis
WO2020016417A1 (en) * 2018-07-19 2020-01-23 Ichnos Sciences S.A. Liquid antibody formulation
WO2020063668A1 (zh) * 2018-09-25 2020-04-02 信达生物制药(苏州)有限公司 包含抗ox40抗体的制剂、其制备方法及其用途
US20220273796A1 (en) * 2019-07-19 2022-09-01 Ichnos Sciences SA Lyophilized antibody formulation
WO2021190582A1 (zh) * 2020-03-25 2021-09-30 江苏恒瑞医药股份有限公司 一种抗ox40抗体药物组合物及其用途

Also Published As

Publication number Publication date
MX2024004619A (es) 2024-07-12
TW202323280A (zh) 2023-06-16
CL2024001157A1 (es) 2024-11-15
WO2023061424A1 (en) 2023-04-20
AU2022367611A1 (en) 2024-05-02
US20250282882A1 (en) 2025-09-11
IL312138A (en) 2024-06-01
EP4415754A1 (en) 2024-08-21
JP2024538140A (ja) 2024-10-18
CA3235879A1 (en) 2023-04-20
PE20241351A1 (es) 2024-07-03
CN118541166A (zh) 2024-08-23
EP4415754A4 (en) 2025-09-24

Similar Documents

Publication Publication Date Title
US11612659B2 (en) Anti-CD40 antibody formulation delivery device
US10899841B2 (en) Anti-BAFFR antibody formulations and methods of use thereof
US20180008707A1 (en) Stable liquid formulation for monoclonal antibodies
CN104768578A (zh) 稳定的低粘度抗体配制品
TWI764097B (zh) 包含抗ｃｄ４７抗體的製劑及其製備方法和用途
US20230173069A1 (en) Formulation comprising anti-il-23p19 antibody, method for preparing same and use thereof
KR20240109250A (ko) 항ox40 단일클론 항체를 포함하는 약학적 제제
WO2018124948A1 (ru) ВОДНАЯ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ РЕКОМБИНАНТНОГО МОНОКЛОНАЛЬНОГО АНТИТЕЛА К ФНОα
KR20240100493A (ko) 항-cd22 항체의 수성 제제 및 이의 용도
HK40114522A (zh) 包含抗-ox40单克隆抗体的药物制剂
EA052372B1 (ru) Фармацевтическая композиция, содержащая моноклональное антитело к ox40
WO2024083074A1 (en) Formulations containing anti-tigit antibody and methods of use thereof
HK40059591A (en) Preparations containing anti-cd47 antibody, and preparation method and use therefor
US20240415769A1 (en) Formulations
TW202342098A (zh) 含有ｐｄ－１抗體的穩定高濃度氯化鈉配製物及其使用方法
EP4548931A1 (en) Anti-pcsk9 antibody preparation and use thereof
CN118175989A (zh) 制剂

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000